<DOC>
	<DOCNO>NCT00883727</DOCNO>
	<brief_summary>This clinical trial aim find safety efficacy adult mesenchymal stem cell patient myocardial infarction .</brief_summary>
	<brief_title>Ex Vivo Cultured Bone Marrow Derived Allogenic MSCs AMI</brief_title>
	<detailed_description />
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Plasma-lyte 148</mesh_term>
	<criteria>Patients STEMI age 20 70 year , either male female nonchild bear potential , 2 day successful PCI . Patient global leave ventricular systolic dysfunction ejection fraction &lt; 50 % &gt; 30 % . ECG sign acute anterior MI STelevation ≥ 2 mm least 2 follow lead I , AVL , V1V6 , ECG sign acute inferoposterior MI STelevation ≥1 mm follow lead II , III , V5V6 STelevation ≥ 2 mm least 2 lead . The target lesion locate proximal section leave anterior descending , leave circumflex right coronary artery . Patient acute myocardial infarction within 10 day prior IP administration . Normal liver renal function . Able understand study information provide . Able give voluntary write consent . History acute/chronic inflammatory condition severe aortic stenosis insufficiency ; severe mitral stenosis severe mitral insufficiency . Severe comorbidity associate reduction life expectancy le 1 year . Advanced renal dysfunction creatinine ≥ 2mg % . Advanced hepatic dysfunction . Have clinically serious and/or unstable intercurrent infection , medical illness condition uncontrolled whose control , opinion Investigator , may jeopardize participation study complication therapy</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>mesenchymal stem cell</keyword>
	<keyword>myocardial infarction</keyword>
</DOC>